Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis
Effectiveness of a Home-Based Therapeutic Exercise Program and Transcranial Direct Current Stimulation (tDCS) as a Treatment for Fatigue in Patients With Multiple Sclerosis
This randomized, double-blind, parallel-group clinical trial aims to assess the effectiveness of a combined intervention consisting of a home-based therapeutic exercise program and transcranial direct current stimulation (tDCS) for the management of fatigue in patients with multiple sclerosis (MS). Fatigue is one of the most disabling and prevalent symptoms in MS, significantly impacting patients' quality of life and functional independence.
Participants diagnosed with MS who meet inclusion criteria will be randomized into two groups:
Group 1: Home-based therapeutic exercise plus sham (placebo) tDCS
Group 2: Home-based therapeutic exercise plus active tDCS
The intervention will span a defined period, with tDCS sessions applied over the dorsolateral prefrontal cortex (DLPFC) using a standard montage and parameters validated in previous studies. The sham stimulation group will follow identical procedures without active current delivery, preserving blinding for participants and evaluators.
The therapeutic exercise program is designed to be feasible for home implementation, targeting key domains affected in MS such as strength, endurance, balance, and mobility. Exercises will be prescribed based on individual patient assessments and progressively adjusted throughout the intervention period.
Primary outcome measures will include functional capacity, evaluated through the Six-Minute Walk Test (6MWT), and fatigue levels, assessed via the Fatigue Severity Scale (FSS) and a Visual Analogue Scale (VAS) for fatigue. Secondary observations may include adherence rates to the exercise program and subjective reports of tolerability and perceived benefits.
This trial seeks to explore whether combining a physical intervention (exercise) with a neuromodulation technique (tDCS) can offer additive benefits in managing fatigue, beyond what exercise alone provides. The ultimate goal is to develop accessible, non-pharmacological treatment strategies to improve daily functioning and quality of life for individuals living with multiple sclerosis.
調査の概要
状態
条件
詳細な説明
This study is a randomized, double-blind, controlled clinical trial designed to investigate the efficacy of a combined intervention consisting of a structured home-based therapeutic exercise program and transcranial direct current stimulation (tDCS) for the treatment of fatigue in patients with multiple sclerosis (MS).
Eligible participants will be randomly assigned to one of two parallel groups:
An intervention group receiving a prescribed home-based exercise program in combination with active tDCS.
A control group receiving the same exercise program combined with sham (placebo) tDCS.
The tDCS intervention will target the dorsolateral prefrontal cortex (DLPFC) using a standardized electrode placement, with stimulation parameters based on protocols previously demonstrated to be safe and potentially effective in neurological populations. The sham condition will simulate the sensation of stimulation without delivering an active current, ensuring the integrity of the blinding process for both participants and evaluators.
The therapeutic exercise program will focus on improving muscular strength, cardiovascular endurance, balance, and functional mobility, components known to be affected in individuals with MS. The program will be tailored to individual baseline capabilities and progressively adapted throughout the intervention period to optimize participant engagement and safety.
Primary outcome measures include changes in functional exercise capacity, as assessed by the Six-Minute Walk Test (6MWT), and fatigue severity, evaluated using the Fatigue Severity Scale (FSS) and a Visual Analogue Scale (VAS) for fatigue. Adherence to the intervention and tolerability will also be monitored.
The proposed study addresses a critical need for accessible, non-pharmacological interventions to manage fatigue, one of the most common and disabling symptoms in MS. By combining physical rehabilitation strategies with neuromodulation techniques, the trial aims to determine whether synergistic effects can be achieved, potentially informing future clinical practices aimed at enhancing the quality of life of individuals with multiple sclerosis.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
A Coruña
-
A Coruña、A Coruña、スペイン、15009
- Complexo Hospitalario Universitario de A Coruña
-
Santiago de Compostela、A Coruña、スペイン、15706
- Complexo Hospitalario Universitario de Santiago de Compostela
-
-
Pontevedra
-
Vigo、Pontevedra、スペイン、36214
- Complexo Hospitalario Universitario de Vigo
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Signed written informed consent
- Confirmed diagnosis of multiple sclerosis
- Presence of fatigue associated with multiple sclerosis, defined as a fatigue Visual Analogue Scale (VAS) score equal to or greater than 4
- Functional capacity sufficient to perform the Six-Minute Walk Test (6MWT), assessed by a Functional Ambulation Category (FAC) score of 3 or higher
Exclusion Criteria:
- Presence of any neurological, rheumatological, or other medical condition prior to the diagnosis of multiple sclerosis that could interfere with the study outcomes
- Presence of contraindications for transcranial direct current stimulation (tDCS), such as having a pacemaker, a history of epillepsy, pregnancy, implanted intracranial electrodes, defibrillator, or similar electronic devices.
- Cognitive impairment that limits the participant's ability to collaborate with study procedures.
- Any changes in physical therapy or pharmacological treatments for multiple sclerosis and/or fatigue that are not specified by the study protocol.
- Occurrence of a multiple sclerosis relapse or disease progression with functional repercussions during the study period.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Exercise Plus Active tDCS
Participants assigned to this arm will complete a home-based therapeutic exercise program combined with active transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC).
Stimulation parameters will follow validated protocols.
Participants and outcomes assessors will be blinded to the assignment.
|
Participants will engage in a structured home-based therapeutic exercise program administered via a smartphone application.
The program consists of targeted strength training, stretching routines, and proprioceptive exercises designed to address functional impairments commonly observed in individuals with multiple sclerosis.
Each session will have an approximate duration of 20 to 30 minutes.
Participants are required to complete a minimum of three sessions per week for the duration of the intervention phase.
Transcranial direct current stimulation (tDCS) targeting the left dorsolateral prefrontal cortex (DLPFC).
Stimulation will be delivered using a standard electrode montage, with the anode positioned over the left DLPFC and the cathode over the contralateral supraorbital area.
The stimulation parameters will include a current intensity of 1.5 mA applied for 20 minutes per session, with a ramp-up and ramp-down phase of 10 seconds each at the beginning and end of stimulation, respectively.
Sessions will be conducted five days per week over a two-week period, for a total of 10 sessions.
他の名前：
|
|
プラセボコンパレーター：Exercise Plus Sham tDCS
Participants assigned to this arm will complete a home-based therapeutic exercise program combined with sham transcranial direct current stimulation (tDCS).
Sham stimulation will mimic the sensation of tDCS without delivering an active current.
Participants and outcomes assessors will be blinded to the assignment.
|
Participants will engage in a structured home-based therapeutic exercise program administered via a smartphone application.
The program consists of targeted strength training, stretching routines, and proprioceptive exercises designed to address functional impairments commonly observed in individuals with multiple sclerosis.
Each session will have an approximate duration of 20 to 30 minutes.
Participants are required to complete a minimum of three sessions per week for the duration of the intervention phase.
Participants assigned to the sham tDCS condition will receive identical electrode placement to the active tDCS group, with the anode over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the contralateral supraorbital area.
The stimulation device will deliver an initial ramp-up phase of 10 seconds of actual stimulation after which no current will be delivered for 1180 seconds, and ending by a ramp-down phase of 10 seconds, The total session duration will match that of the active group (20 minutes), ensuring participant blinding.
Sessions will occur five days per week over a two-week period, for a total of 10 sessions.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Fatigue Severity Measured by the Fatigue Severity Scale (FSS)
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS).
The primary endpoint is the percentage reduction in the FSS total score compared to baseline.
A clinically meaningful improvement is defined as a reduction greater than 20% in the FSS total score (approximately 13 points).
Fatigue assessments will be conducted at baseline (prior to the intervention), at 10 days after the final tDCS session, at 3 months, and at 6 months post-intervention to evaluate both immediate and sustained effects.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Change in Fatigue Severity Measured by Visual Analogue Scale (VAS) for Fatigue
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Fatigue severity will be assessed using a Visual Analogue Scale (VAS) for fatigue.
The primary endpoint is the change in VAS fatigue score compared to baseline.
A clinically meaningful improvement is defined as a reduction of at least 2 points on the VAS.
Fatigue assessments will be conducted at baseline (prior to the intervention), at 10 days after the final tDCS session, at 3 months, and at 6 months post-intervention to evaluate both immediate and sustained effect
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Functional Capacity Measured by the Six-Minute Walk Test (6MWT)
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
The Six-Minute Walk Test (6MWT) will be used to assess participants' functional exercise capacity by recording the total distance walked in six minutes.
This test reflects submaximal functional endurance and mobility.
Changes in distance walked will be compared to baseline measurements to evaluate improvements.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Handgrip Strength Measured by Hand Dynamometry
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Handgrip strength will be measured using a standardized hand dynamometer (Jamar device).
The maximal grip strength will be recorded in kilograms with one decimal place of precision.
The values obtained will be compared with baseline measurements to assess changes in upper limb strength following the intervention.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Change in Quality of Life Measured by EuroQol 5D (EQ-5D)
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Participants' self-perceived health status and quality of life will be evaluated using the EuroQol 5D questionnaire (EQ-5D).
Changes from baseline in the EQ-5D score will be analyzed to determine whether the intervention has an impact on the participant's perception of overall health and quality of life.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Change in Exercise Tolerance Measured by Distance Walked in the 6-Minute Walk Test (6MWT)
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Exercise tolerance will be assessed using the 6-Minute Walk Test (6MWT).
The total distance walked (in meters) during the test will be recorded.
Changes from baseline in the distance walked will be analyzed to evaluate the effect of the intervention on exercise tolerance.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Change in Perceived Exertion After 6-Minute Walk Test Measured by Borg Rating of Perceived Exertion (RPE) Scale
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Participants' perception of exertion after the 6-Minute Walk Test (6MWT) will be assessed using the Borg Rating of Perceived Exertion (RPE) Scale (0-10).
Changes from baseline in Borg RPE scores will be analyzed to evaluate the effect of the intervention on perceived exertion during exercise.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Tolerance to tDCS Measured by Visual Analogue Scale (VAS)
時間枠：Immediately after each stimulation session
|
Tolerance to tDCS will be evaluated through a specific VAS (0 to 10)
|
Immediately after each stimulation session
|
|
Adverse Events Associated With tDCS Application
時間枠：Throughout the Intervention Period (during each session)
|
The frequency, intensity, and duration of adverse events related to tDCS (e.g., itching, tingling, headache) will be monitored through structured questionnaires completed after each session.
|
Throughout the Intervention Period (during each session)
|
|
Change in Self-Perceived Health Status Measured by EuroQol Visual Analogue Scale (EQ-VAS, EuroQol Thermometer)
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Participants' self-perceived health status will be evaluated using the EuroQol Visual Analogue Scale (EQ-VAS, EuroQol Thermometer), a visual analogue scale ranging from 0 to 100.
Changes from baseline in the EQ-VAS score will be analyzed to determine whether the intervention has an impact on the participant's perception of overall health statu
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Participant Satisfaction Assessed by a 5-Point Nominal Satisfaction Scale
時間枠：Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
Participants will evaluate their satisfaction with the intervention using a nominal 5-point satisfaction scale ranging from much worse to much better than expected.
|
Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline
|
|
Program Adherence Measured Through the ReHub Platform
時間枠：Throughout the 12-Week Exercise Program
|
Adherence to the exercise program will be monitored via the ReHub platform, recording the percentage of completed sessions over the total prescribed.
|
Throughout the 12-Week Exercise Program
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター：Jacobo Formigo, Dr,、Complexo Hospitalario Universitario de A Coruña
出版物と役立つリンク
一般刊行物
- Linnhoff S, Haghikia A, Zaehle T. Effects of repetitive twice-weekly transcranial direct current stimulations on fatigue and fatigability in people with multiple sclerosis. Sci Rep. 2023 Apr 11;13(1):5878. doi: 10.1038/s41598-023-32779-y.
- Mortezanejad M, Ehsani F, Masoudian N, Zoghi M, Jaberzadeh S. Comparing the effects of multi-session anodal trans-cranial direct current stimulation of primary motor and dorsolateral prefrontal cortices on fatigue and quality of life in patients with multiple sclerosis: a double-blind, randomized, sham-controlled trial. Clin Rehabil. 2020 Aug;34(8):1103-1111. doi: 10.1177/0269215520921506. Epub 2020 May 12.
- Bertoli M, Tataranni A, Porziani S, Pasqualetti P, Gianni E, Grifoni J, L'Abbate T, Armonaite K, Conti L, Cancelli A, Cottone C, Marinozzi F, Bini F, Cecconi F, Tecchio F. Effects on Corticospinal Tract Homology of Faremus Personalized Neuromodulation Relieving Fatigue in Multiple Sclerosis: A Proof-of-Concept Study. Brain Sci. 2023 Mar 29;13(4):574. doi: 10.3390/brainsci13040574.
- Xian C, Barbi C, Goldsworthy MR, Venturelli M, Sidhu SK. The interaction between metaplastic neuromodulation and fatigue in multiple sclerosis. J Neurol Sci. 2023 Jan 15;444:120521. doi: 10.1016/j.jns.2022.120521. Epub 2022 Dec 11.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2024/103.
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。